Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. April 2023 08:35 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)

Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM...
04. April 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

OCALA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
03. April 2023 06:30 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones –...
30. März 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise

OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
27. März 2023 09:05 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
16. März 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
08. März 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

OCALA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
06. März 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Issues Letter to Stockholders

Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and...
28. Februar 2023 08:45 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
17. Februar 2023 08:55 ET | Quelle: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”

OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...

Vorherige Seite

Nächste Seite